Ran Reshef, MD
Division of Hematology/Oncology
Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.
- Multiple Myeloma
- Blood and Marrow Stem Cell Transplantation
- Bone Marrow Transplant
Sternberg Research Award, Abramson Cancer Center, University of Pennsylvania (2008)
Bradley Fellow Research Award, Department of Medicine, University of Pennsylvania (2011)
Austrian Junior Faculty Award, Department of Medicine, University of Pennsylvania (2012)
Amy Strelzer Manasevit Award for the Study of Post-Transplant Complications, National Marrow Donor Program (2013)
Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta, SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie J, Vonderheide RH, Porter DL (2012). “Effect of Blocking Lymphocyte Chemotaxis on Visceral Graft-vs-Host Disease.” N Engl J Med 367:135-145
Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL (2015). “High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning” J Clin Oncol 33:2392-2398.
Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter and Ran Reshef (2017) "Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis" Blood 129:906-916